Medical Review Board
Trust and accuracy are important, especially during times of uncertainty. That’s why our content is reviewed by at least one of our Medical Review Board members, a highly qualified team of well-recognized doctors in various disciplines in and around oncology.
We have composed this board to ensure the safety and confidence of our community, alleviating concerns of validity and accuracy. Our board verifies that articles containing medical information reflect the latest in evidence-based research and health information.
In addition to ensuring content quality, the Medical Review Board members will also participate with our Community through various forums, including seminars, panel discussions, and designated Office Hours.
Meet our Medical Review Board experts
Torie CroogRadiation Oncologist at Sibley Memorial Hospital
Victoria J. Croog, M.D. currently works in the Department of Radiation Oncology at the Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, as well as a clinical associate in the Department of Radiation Oncology at The Johns Hopkins Hospital. Dr. Croog is board certified in radiation oncology by the American Board of Radiology.
Dr. Croog has expertise in breast cancer, gastrointestinal cancer, gynecologic cancer, brain cancer and tumors of the central nervous system. She earned her medical degree from Harvard Medical School and completed a residency in radiation oncology at Memorial Sloan-Kettering Cancer Center.
Dr. Croog is involved with several committees at Sibley Memorial Hospital, including the Medical Executive Committee, the IRB/Research Review Committee, the Cancer Committee and the Radiation Safety Committee. She is also a member of the American Society of Clinical Oncology and the American Society of Radiation Oncology.
Dr. Croog has been published in numerous peer-reviewed journals and has presented research at various conferences, such as the American Society of Clinical Oncology’s annual meeting.
Jake PrigoffOncology Physician at New York Presbyterian Hospital
Dr. Prigoff’s passion to change the face of healthcare is driven by his own teenage battle with stage IV Hodgkin’s lymphoma. His experience as a patient and a physician gives him a unique perspective on the needs of cancer patients and their support system. He received his treatment at Columbia University Medical Center – 12 years later, he returned to that same institution, but this time as a physician.
Dr. Prigoff earned his bachelor’s degree in economics from the University of Michigan in Ann Arbor and then his medical degree at The Icahn School of Medicine at Mount Sinai in New York City. Afterwards, he remained in NYC for residency in general surgery at New York Presbyterian Hospital – Columbia and a fellowship in Surgical Education at Columbia University Irving Medical Center. Dr. Prigoff has presented his academic work at conferences across the United States and published extensively in the fields of oncology, general surgery, and surgical education.
Dr. Prigoff is a member of Alpha Omega Alpha, the national medical honor society, and has received a variety of awards from both academic institutions and philanthropic foundations including The Cecilia Benevisto Courage Award from The SASS Foundation for Medical Research.
Lea Ann BiaforaOncology Nurse, Founder & CEO of Beacon Advocates
With 30 years’ experience in the healthcare industry, Lea Ann has a unique combination of experience as a certified oncology nurse and as an accomplished leader within the health care business sector. Lea Ann has devoted her career to assisting cancer patients in acute care settings, academic medical centers, and community settings.
Lea Ann understands the importance of patient advocacy, and she recognizes the widened systemic gaps in cancer care. After years of witnessing her family, friends, and patients struggle through the frustrating inadequacies within the healthcare system, Lea Ann created a concierge care management model that treats individuals living with cancer holistically – as an individual person, not as a patient.
Building upon her strong relationships with doctors and insurance companies, she navigates the healthcare delivery system and the science of cancer care with ease, eliminating barriers to care in the process. Her approach helps to create transparency in communication to promote shared and informed decision-making while strengthening the physician and patient relationship.
Her combined experience has proven to be a trustworthy resource as she advocates for patients. Now, Lea Ann’s nurse-led approach helps to create transparency to promote shared and informed decision-making while strengthening the physician and patient relationship. She has gathered a specialized and experienced team of oncology nurses who listen and address patients’ needs and wants so they can receive the best cancer care available.
Micheal GuerreraPediatric Oncologist
Dr. Michael F. Guerrera, M.D., currently acts as the Director of the Comprehensive Hemostasis and Thrombosis Program at Children’s National Hospital, where he has practiced for almost 10 years. Dr. Michael’s dedication to pediatrics after he completed his Pediatric residency at Connecticut Children’s Medical Center (University of Connecticut Program) and fellowship in Pediatric Hematology Oncology at Children’s National Medical Center.
Along with his commitment to the practice of medicine, Dr. Michael supports the medical community through education. Dr. Michael received a Certificate in Adult Education from the George Washington University School of Education and served as the Pediatric Hematology Oncology fellowship director for eight years, remaining involved in fellow education and research oversight.
With over 20 years of experience in hematology, bleeding and thrombotic disorders, Dr. Michael has earned many prestigious recognitions, including 2018 Physician of the Year from the National Hemophilia Foundation (NHF), Northern Virginia Magazine Top Doctor in 2020 and 2019, and Washingtonian Top Doctor for the past five years. Dr. Michael is thrilled to bring his expertise and dedication to the OneVillage team.
As an elected member of the Region III/MidAtlantic oversight committee for the CDC/HRSA Hemophilia Treatment Center Grants and an active member of the Institutional Review Board, Dr. Micheal brings important experience that informs his passion for joining out Medical Review Board team.
Ashlea ChandlerGlobal Clinical Lead at IQVIA
Ashlea’s current serves as the Global Clinical Lead at IQVIA, with responsibility for delivery of all clinical aspects of clinical studies. Her role is focused on overseeing daily clinical trial activities, which include monitoring and site management, recruitment strategy development, and driving study enrollment. Ashlea’s prior experience with oncology drives her passion for connecting patients with information about clinical trials that may be a fit for their demographic and diagnosis.
As a creative clinical project manager with extensive clinical research experience, from project design to development, Ashlea is responsible for coordinating the clinical project team to ensure high performance and productivity, optimal utilization, minimal turnover and proper documentation of processes. Ashlea’s communication skills ensure that, as the primary point of contact for the clinical aspects of designated projects, there are successful cross functional relationships with internal and external participants.
Prior to working at IQVIA, Ashlea was the clinical project manager for the Polyethnic-1000 (P-1000) initiative. P-1000 is a diverse cancer biorepository / data commons platform, established to support multi-center cancer genomic clinical trials. These trials are designed to improve the outcomes for cancer patients of multiple ethnicities, including those who are generally under-represented in research. She played a key role in developing and implementing strategic processes for the operational management of the P-1000 initiative, leading to the received award of up to $2.1 million in grant funding. This funding supports seven new research projects that will study a wide array of cancers in minority patients by using sequencing and other technologies to investigate the role of ethnicity in cancer. At Actinium Pharmaceuticals, Ashlea worked as a clinical trial manager on a Phase I/II study investigating the maximum tolerated dose (MTD) of lintuzumab-Ac225 when added to venetoclax in refractory/relapsed Acute Myeloid Leukemia (AML) patients.
Ashlea joins the OneVillage Medical Review Board to help provide accurate and straightforward information on clinical trials and research. Her special talent for high quality communication will help her connect with OneVillage community members and provide a strong foundation for future clinical trial features available on OneVillage.